| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/2004 | WO2004063151A2 Novel tyrosine kinase inhibitors |
| 07/29/2004 | WO2004063150A2 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
| 07/29/2004 | WO2004063147A1 Salts and solvates of glucagon antagonists |
| 07/29/2004 | WO2004063146A1 Hydroxamic acid derivatives having anti-inflammatory action |
| 07/29/2004 | WO2004062729A1 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | WO2004062695A1 Orally deliverable pharmaceutical composition containing protein pump inhibitors |
| 07/29/2004 | WO2004062693A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy |
| 07/29/2004 | WO2004062692A1 Formulation of poorly water-soluble active substances |
| 07/29/2004 | WO2004062680A1 Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
| 07/29/2004 | WO2004062676A1 -modified nucleoside derivatives for treating flaviviridae infections |
| 07/29/2004 | WO2004062675A1 Method of modulating il-6 |
| 07/29/2004 | WO2004062674A2 Substituted polyamines as inhibitors of bacterial efflux pumps |
| 07/29/2004 | WO2004062673A1 Anti-protozoal compositions comprising diclazuril |
| 07/29/2004 | WO2004062672A1 Multivitamin regimen for renal patients |
| 07/29/2004 | WO2004062671A2 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| 07/29/2004 | WO2004062669A1 Use of a macrolide compound for treating dry eye |
| 07/29/2004 | WO2004062668A1 Ophthalmic compositions containing loratadine |
| 07/29/2004 | WO2004062666A2 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia |
| 07/29/2004 | WO2004062663A1 Use of substituted 2-phenylbenzimidazoles as medicaments |
| 07/29/2004 | WO2004062662A1 Aminoindazole derivatives and use thereof as kinase inhibitors |
| 07/29/2004 | WO2004062660A1 Contact lens and eye drop rewetter compositions and their uses |
| 07/29/2004 | WO2004062659A1 Methods and compositions for preventing/reducing the severity of side effects of chemotherapy and/or radiotherapy |
| 07/29/2004 | WO2004062658A1 A method of treatment or prophylaxis of symptoms of herpes viral infection |
| 07/29/2004 | WO2004062657A1 Acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
| 07/29/2004 | WO2004062656A1 Compositions and methods for improving the condition of patients suffering from copd and other diseases |
| 07/29/2004 | WO2004062655A1 Alpha-aminoamide derivatives useful as antimigraine agents |
| 07/29/2004 | WO2004062654A1 Use of cyclin d1 inhibitors |
| 07/29/2004 | WO2004062653A2 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis |
| 07/29/2004 | WO2004062652A1 Prevention and treatment of alzheimer's disease |
| 07/29/2004 | WO2004062646A1 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/29/2004 | WO2004062645A1 Microspheres containing amphotericin b |
| 07/29/2004 | WO2004062638A1 Hinokitiol-based composition for personal hygiene care |
| 07/29/2004 | WO2004062632A1 Topical stabilized prostaglandin e compound dosage forms |
| 07/29/2004 | WO2004062629A2 Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells |
| 07/29/2004 | WO2004062626A2 Composition and method for treating age-related disorders |
| 07/29/2004 | WO2004062624A2 Method of treating nausea, vomiting, retching or any combination thereof |
| 07/29/2004 | WO2004062623A2 Method of treating functional bowel disorders |
| 07/29/2004 | WO2004062620A2 Paricalcitol as a chemotherapeutic agent |
| 07/29/2004 | WO2004062617A2 Composition and method for treatment of bacterial vaginal infections |
| 07/29/2004 | WO2004062616A2 Method of treating cognitive decline due to sleep deprivation and stress |
| 07/29/2004 | WO2004062614A2 Carbohydrate conjugates to prevent abuse of controlled substances |
| 07/29/2004 | WO2004062613A2 Hiv integrase inhibitors |
| 07/29/2004 | WO2004062611A2 Anti-inflammatory cyclooxygenase-2 selective inhibitors |
| 07/29/2004 | WO2004062610A2 4',4''-SUBSTITUTED 3α-(DIPHENYLMETHOXY)TROPANE ANALOGS FOR TREATMENT OF MENTAL DISORDERS |
| 07/29/2004 | WO2004062607A2 Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb |
| 07/29/2004 | WO2004062606A2 Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal |
| 07/29/2004 | WO2004062605A2 Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal |
| 07/29/2004 | WO2004062604A2 Treatment of cancer with 2-deoxyglucose |
| 07/29/2004 | WO2004062603A2 Methods of treating lung diseases |
| 07/29/2004 | WO2004062597A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 07/29/2004 | WO2004062596A2 Antineoplastic ether lipid compounds having a four carbon backbone |
| 07/29/2004 | WO2004062593A2 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon |
| 07/29/2004 | WO2004062590A2 Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites |
| 07/29/2004 | WO2004062588A2 Water-soluble polymeric bone-targeting drug delivery system |
| 07/29/2004 | WO2004062586A2 Antineoplastic ether lipid compounds |
| 07/29/2004 | WO2004062582A2 Combination therapy for anticoagulation |
| 07/29/2004 | WO2004062580A2 Odorless formulation for treating mucosal discontinuities |
| 07/29/2004 | WO2004062578A2 Methods for reducing mortality associated with acute myocardial infarction |
| 07/29/2004 | WO2004062577A2 Two or more enteric materials to regulate drug release |
| 07/29/2004 | WO2004062576A2 Methods for treating ocular diseases |
| 07/29/2004 | WO2004062575A2 Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses |
| 07/29/2004 | WO2004062569A2 Cardiolipin compositions their methods of preparation and use |
| 07/29/2004 | WO2004062564A2 Sedative non-benzodiazepine formulations |
| 07/29/2004 | WO2004062561A2 Pharmaceutical compositions comprising fentanyl for intranasal delivery |
| 07/29/2004 | WO2004062557A2 Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | WO2004062552A2 Pharmaceutical composition containing a nsaid and a benzimidazole derivative |
| 07/29/2004 | WO2004062380A2 Modulating cholesterol using wild rice |
| 07/29/2004 | WO2004052349A3 Compositions comprising a combination of diphenyl ura impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 07/29/2004 | WO2004050629A3 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |
| 07/29/2004 | WO2004050614A3 Flavanols and procyanidins promote homeostasis |
| 07/29/2004 | WO2004050123A3 Concentrated liquid valdecoxib composition |
| 07/29/2004 | WO2004050070A3 Composition comprising pseudoephedrine and domperidone for preventing snoring |
| 07/29/2004 | WO2004050039A3 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 07/29/2004 | WO2004050030A3 Anti-sickling agents |
| 07/29/2004 | WO2004050021A3 Methods and compositions for applying pharmacologic agents to the ear |
| 07/29/2004 | WO2004050011A3 High enantiomeric purity dexanabinol for pharmaceutical copositions |
| 07/29/2004 | WO2004047866A3 Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 07/29/2004 | WO2004047819A3 Composition and its use for treating neuropathic sensory loss |
| 07/29/2004 | WO2004047798A3 Formulations of finasteride |
| 07/29/2004 | WO2004047713A3 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 07/29/2004 | WO2004046091A3 Biaromatic compounds which activate ppar-gama type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 07/29/2004 | WO2004045560A3 Combination of monounsaturated fatty acids and estogen, and their use |
| 07/29/2004 | WO2004045533A3 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 07/29/2004 | WO2004045515A3 Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| 07/29/2004 | WO2004043993A3 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use |
| 07/29/2004 | WO2004043336A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 07/29/2004 | WO2004041777A3 Heteroarylpiperidine modulators of chemokine receptor activity |
| 07/29/2004 | WO2004041297A3 Modified cytokines for use in cancer therapy |
| 07/29/2004 | WO2004041292A3 C-type lectin binding molecules, identification and uses thereof |
| 07/29/2004 | WO2004041178A3 A protectant for uv-induced skin damage |
| 07/29/2004 | WO2004041162A3 Inhibitors of akt activity |
| 07/29/2004 | WO2004037233A3 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| 07/29/2004 | WO2004037175A3 Compositions and methods for treating human papillomavirus-mediated disease |
| 07/29/2004 | WO2004037173A3 Method for treating erectile dysfunction and increasing libido in men |
| 07/29/2004 | WO2004035536A3 Azo compounds for type i phototherapy |
| 07/29/2004 | WO2004034959A3 Multiparticulate modified release composition comprising beraprost |
| 07/29/2004 | WO2004033725A3 Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene |
| 07/29/2004 | WO2004033423A3 Anticancer compounds |
| 07/29/2004 | WO2004032873A3 Therapeutic combination of carnitine and antioxidant polyphenols |
| 07/29/2004 | WO2004032866A3 Therapeutic formulations |